Crohn’s Disease Therapeutics Market Outlook 2031
The global Crohn’s disease therapeutics market size was USD 9.98 Billion in 2022 and is expected to reach USD 17.15 Billion by 2031 expand at a significant CAGR 6.2% during the forecast period, 2023–2031. The growth of the market is attributed to the growing disease prevalence, along with a growth in the number of pipeline drugs.
Crohn's disease is an inflammatory bowel illness that affects the intestines (IBD). It causes digestive system inflammation, which can result in stomach discomfort, severe diarrhea, tiredness, weight loss, and malnutrition. Crohn's disease causes inflammation in different parts of the digestive system in different persons.
This inflammation frequently extends into the bowel's deeper layers. Crohn's disease is a painful and debilitating condition that can occasionally result in life-threatening complications. While there is no known cure for Crohn's disease, treatments can significantly reduce symptoms and potentially lead to long-term remission and inflammatory healing.
Many patients with Crohn's disease can operate normally after receiving therapy. Any region of your small or large intestine can be affected by Crohn's disease, and it can be continuous or encompass numerous segments. The illness is limited to the colon, which is a portion of the large intestine, in some patients. Crohn's disease signs and symptoms can range from minor to severe.
They generally appear gradually, although they can sometimes appear suddenly and without notice. There may also be times when you have no indications or symptoms (remission). Diarrhea, fever, fatigue, abdominal discomfort and cramps, blood in your stool, mouth sores, reduced appetite and weight loss, and pain or drainage at or around the anus owing to inflammation from a tunnel into the skin are all signs and symptoms of the illness while it is active (fistula).
Inflammation of the skin, eyes, and joints, inflammation of the liver or bile ducts, kidney stones, iron shortage (anemia), and delayed growth or sexual development in children are all symptoms of severe Crohn's disease. Doctor will not be able to identify Crohn's disease just on a single test result. They will start by ruling out any other potential reasons of your symptoms.
To make a diagnosis, your doctor may perform a variety of tests, including Blood tests can assist your doctor in looking for signs of potential issues such as anemia and inflammation. A stool test can assist your doctor in detecting blood in your gastrointestinal system. To acquire a better view of the inside of your upper gastrointestinal system your doctor may recommend an endoscope, a colonoscopy may be ordered by your doctor to check the big intestine, CT scans and MRI scans provide more information to your doctor than a standard X-ray, doctor can view particular regions of your tissues and organs with both tests, during an endoscopy or colonoscopy, your doctor will most likely take a tissue sample, or biopsy, to examine your digestive tract tissue more closely.
Although there is no cure for Crohn's disease, the condition can be controlled. There are a number of therapy options available to help you manage the severity and frequency of your symptoms. The treatment options include medications, surgery, and diet. Crohn's disease research is still underway in the terms of achieving more effective therapies and, ultimately, a cure. However, symptoms can be well controlled, and remission is possible.
Crohn’s Disease Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of Crohn’s disease in developing countries as a result of industrialization, environmental variables such as changes in sunlight exposure, dietary changes, smoking, and hereditary characteristics are projected to drive the market growth.
- Growing efforts on development of biosimilars is anticipated to propel the market growth during the forecast period.
- Low cost of biosimilars and increased access to biologic therapies are major factors fueling the market growth in the coming years.
- Increase in the number of pipeline drugs is anticipated to drive the market growth during the forecast period.
- High costs of deploying essential equipment to treat Crohn's disease is anticipated to impede the market growth during the forecast period.
- Lack of expertise in providing therapy in rural and underdeveloped areas presents as key challenge that can hamper the market growth during the forecast period.
- Increased focus on R&D for development of innovative biological agents and anti-cytokine agents with diverse mechanisms of action, as well as the use of stem cells in disease treatment is projected to create lucrative opportunities for the market players.
Scope of the Crohn’s Disease Therapeutics Market Report
The report on the global Crohn’s disease therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Crohn’s Disease Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Therapy Type (Non-Surgical [Anti-Inflammatory, Immune system suppressors, Antibiotics, and Others], and Surgical)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited
|
Crohn’s Disease Therapeutics Market Segment Insights
Non-surgical segment is expected to account for a key share
Based on therapy type, the Crohn’s disease therapeutics market is bifurcated into non-surgical and surgical. The non-surgical segment is further sub segmented into anti-inflammatory, immune system suppressors, antibiotics, and others. The non-surgical segment is expected to account for a key share of the market during the forecast period owing to growing adoption of anti-inflammatory drugs.
Anti-inflammatories are drugs that are used as first-line treatment as they are more targeted and effective. On the other hand, the immune system suppressors segment is anticipated to expand at a rapid pace during the forecast period owing to its safety and efficacy. The segment is projected to be driven by lower rates of mortality, hospitalization, and surgery, as well as better patient quality of life.
Immune system suppressors are presently being developed by companies like Genentech Inc. and Celgene Corporation to address this disease. For example, Genentech Inc.'s etrolizumab, an immune system suppressor, is now being studied in clinical trials. In phase II clinical trials, this medication showed promise in terms of safety and effectiveness. The approval of these goods might help this market develop in the future.
North America is anticipated to dominate
On the basis of regions, the Crohn’s disease therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to established R&D infrastructure, the discovery of innovative treatments, and the growing prevalence of the condition.
Due to the increasing disease's incidence and well-developed healthcare infrastructure, new treatment approaches are being developed and made available to sufferers. On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to change in dietary habits. Japan and China are regarded to be the region's most potential markets.
Europe is expected to exhibit a rapid growth rate in the coming years owing to well-established healthcare infrastructure, as well as an increase in illness prevalence and R&D activities.
Segments
The global Crohn’s disease therapeutics market has been segmented on the basis of
Therapy Type
- Non-Surgical
- Anti-Inflammatory
- Immune system suppressors
- Antibiotics
- Others
- Surgical
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Allergan
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Celgene Corporation
- Perrigo Company PLC
- Ferring B.V.
- Salix Pharmaceuticals
- Gilead Sciences Inc.
- Genentech Inc.
- UCB India Private Limited
Competitive Landscape
Key players competing in the Crohn’s disease therapeutics market includes Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
